These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

943 related articles for article (PubMed ID: 11728801)

  • 1. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system.
    Nordberg J; Arnér ES
    Free Radic Biol Med; 2001 Dec; 31(11):1287-312. PubMed ID: 11728801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The thioredoxin antioxidant system.
    Lu J; Holmgren A
    Free Radic Biol Med; 2014 Jan; 66():75-87. PubMed ID: 23899494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
    Tonissen KF; Di Trapani G
    Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A thioredoxin reductase and/or thioredoxin system-based mechanism for antioxidant effects of ambroxol.
    Huang J; Xu J; Tian L; Zhong L
    Biochimie; 2014 Feb; 97():92-103. PubMed ID: 24103200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue.
    Nordberg J; Zhong L; Holmgren A; Arnér ES
    J Biol Chem; 1998 May; 273(18):10835-42. PubMed ID: 9556556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Thioredoxin System for Cancer Therapy.
    Zhang J; Li X; Han X; Liu R; Fang J
    Trends Pharmacol Sci; 2017 Sep; 38(9):794-808. PubMed ID: 28648527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Mammalian Thioredoxin Reductase Inhibitors.
    Arnér ESJ
    Handb Exp Pharmacol; 2021; 264():289-309. PubMed ID: 32767140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate.
    Zhang H; Cao D; Cui W; Ji M; Qian X; Zhong L
    Free Radic Biol Med; 2010 Dec; 49(12):2010-8. PubMed ID: 20951799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thioredoxin system in cell death progression.
    Lu J; Holmgren A
    Antioxid Redox Signal; 2012 Dec; 17(12):1738-47. PubMed ID: 22530689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents.
    Liu Y; Li Y; Yu S; Zhao G
    Curr Drug Targets; 2012 Oct; 13(11):1432-44. PubMed ID: 22876886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selenocysteine in mammalian thioredoxin reductase and application of ebselen as a therapeutic.
    Ren X; Zou L; Lu J; Holmgren A
    Free Radic Biol Med; 2018 Nov; 127():238-247. PubMed ID: 29807162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thioredoxin Cross-Linking by Nitrogen Mustard in Lung Epithelial Cells: Formation of Multimeric Thioredoxin/Thioredoxin Reductase Complexes and Inhibition of Disulfide Reduction.
    Jan YH; Heck DE; Casillas RP; Laskin DL; Laskin JD
    Chem Res Toxicol; 2015 Nov; 28(11):2091-103. PubMed ID: 26451472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads.
    Kaminska KK; Bertrand HC; Tajima H; Stafford WC; Cheng Q; Chen W; Wells G; Arner ES; Chew EH
    Oncotarget; 2016 Jun; 7(26):40233-40251. PubMed ID: 27244886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The thioredoxin system in cancer.
    Arnér ES; Holmgren A
    Semin Cancer Biol; 2006 Dec; 16(6):420-6. PubMed ID: 17092741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity assays of mammalian thioredoxin and thioredoxin reductase: fluorescent disulfide substrates, mechanisms, and use with tissue samples.
    Montano SJ; Lu J; Gustafsson TN; Holmgren A
    Anal Biochem; 2014 Mar; 449():139-46. PubMed ID: 24374250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic characterization of the thioredoxin system in the removal of hydrogen peroxide.
    Pannala VR; Dash RK
    Free Radic Biol Med; 2015 Jan; 78():42-55. PubMed ID: 25451645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo.
    Fang J; Holmgren A
    J Am Chem Soc; 2006 Feb; 128(6):1879-85. PubMed ID: 16464088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Selenium compounds in redox regulation of inflammation and apoptosis].
    Rusetskaya NY; Fedotov IV; Koftina VA; Borodulin VB
    Biomed Khim; 2019 Apr; 65(3):165-179. PubMed ID: 31258141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase.
    Hashemy SI; Ungerstedt JS; Zahedi Avval F; Holmgren A
    J Biol Chem; 2006 Apr; 281(16):10691-7. PubMed ID: 16481328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The thioredoxin system and cancer therapy: a review.
    Mohammadi F; Soltani A; Ghahremanloo A; Javid H; Hashemy SI
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):925-935. PubMed ID: 31367788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.